The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
Jamie Oliver turned down the offer of playing a hobbit in the movie adaptation of the book by JRR Tolkien, the TV chef has revealed.
Children are being put at risk as 11% of posts for permanent children's social workers remain unfilled, experts have warned.
A Network Rail boss who presided over the Christmas trains chaos will not receive a bonus of more than £300,000 when he leaves in February